基本信息
浏览量:9
职业迁徙
个人简介
Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.
研究兴趣
论文共 1643 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jayastu Senapati,Hagop M. Kantarjian,Alexandre Bazinet,Patrick Reville,Nicholas J. Short,Naval Daver,Gautam Borthakur,Alex Bataller,Elias Jabbour,Courtney Dinardo,Fadi Haddad,Koji Sasaki,Uday Popat,Betul Oran,Amin M. Alousi,Sanam Loghavi,Elizabeth Shpall,Guillermo Garcia-Manero,Farhad Ravandi,Tapan M. Kadia
Cancer (2024)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIAno. 5 (2024): 285-297
Yaqi Zhao,Nicholas J. Short,Hagop M. Kantarjian,Ti-Cheng Chang,Pankaj S. Ghate,Chunxu Qu,Walid Macaron,Nitin Jain,Beenu Thakral,Aaron H. Phillips,Joseph Khoury,Guillermo Garcia-Manero, Wenchao Zhang,Yiping Fan, Hui Yang,Rebecca S. Garris,Lewis F. Nasr,Richard W. Kriwacki,Kathryn G. Roberts,Marina Konopleva,Elias J. Jabbour,Charles G. Mullighan
Targeted oncologyno. 2 (2024): 135-141
Elias Jabbour,Gerhard Zugmaier,Vaibhav Agrawal,Pilar Martinez-Sanchez,Jose J. Rifon Roca,Ryan D. Cassaday, Boris Boell,Anita Rijneveld,Maher Abdul-Hay,Francoise Huguet,Thomas Cluzeau,Mar Tormo Diaz,Vladan Vucinic,Jose Gonzalez-Campos,Alessandro Rambaldi,Stefan Schwartz,Celine Berthon,Jesus Maria Hernandez-Rivas,Paul R. Gordon,Monika Brueggemann,Ali Hamidi,Yuqi Chen,Hansen L. Wong, Bharat Panwar,Yuliya Katlinskaya,Ana Markovic,Hagop Kantarjian
American journal of hematologyno. 4 (2024): 586-595
Branko Cuglievan,Hagop Kantarjian, Jeffrey E Rubnitz,Todd M Cooper,C Michel Zwaan,Jessica A Pollard,Courtney D DiNardo,Tapan M Kadia,Erin Guest,Nicholas J Short,David McCall,Naval Daver,Cesar Nunez,Fadi G Haddad,Miriam Garcia,Kapil N Bhalla, Abhishek Maiti,Samanta Catueno,Warren Fiskus,Bing Z Carter,Amber Gibson,Michael Roth,Sajad Khazal,Priti Tewari,Hussein A Abbas,Wallace Bourgeois,Michael Andreeff,Neerav N Shukla,Danh D Truong, Jeremy Connors,Joseph A Ludwig,Janine Stutterheim,Elisabeth Salzer, Kristian L Juul-Dam,Koji Sasaki,Kris M Mahadeo,Sarah K Tasian,Gautam Borthakur, Samantha Dickson,Nitin Jain,Elias Jabbour,Soheil Meshinchi,Guillermo Garcia-Manero,Farhad Ravandi,Eytan M Stein,E Anders Kolb,Ghayas C Issa
Leukemia (2024)
Kashi Raj Bhattarai,Robert J Mobley,Kelly R Barnett,Daniel C Ferguson,Baranda S Hansen,Jonathan D Diedrich,Brennan P Bergeron,Satoshi Yoshimura,Wenjian Yang,Kristine R Crews,Christopher S Manring,Elias Jabbour,Elisabeth Paietta,Mark R Litzow,Steven M Kornblau,Wendy Stock,Hiroto Inaba,Sima Jeha,Ching-Hon Pui, Cheng,Shondra M Pruett-Miller,Mary V Relling,Jun J Yang,William E Evans,Daniel Savic
Nature communicationsno. 1 (2024)
American journal of hematologyno. 4 (2024): 792-796
Issa F. Khouri,Kamal Alzahrani,Hagop Kantarjian,Denai R. Milton,Alison M. Gulbis,Koji Sasaki,Nitin Jain,Nicholas J. Short,Tapan Kadia,May Daher,Hind Rafei,Jin S. Im,David Marin,Amanda L. Olson,Uday Popat,Muzaffar Qazilbash,Jeremy Ramdial,Gabriela Rondon,Samer Srour,Partow Kebriaei,Elizabeth Shpall,Richard Champlin,Elias J. Jabbour
American journal of hematologyno. 5 (2024): 836-843
Leukemiano. 5 (2024): 1-4
加载更多
作者统计
#Papers: 1635
#Citation: 34883
H-Index: 86
G-Index: 138
Sociability: 8
Diversity: 2
Activity: 390
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn